





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/275, 31/415, 31/425, 31/44	A1	(11) International Publication Number: WO 98/06391 (43) International Publication Date: 19 February 1998 (19.02.98)
(21) International Application Number: PCT/IL97/00276		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 14 August 1997 (14.08.97)		
(30) Priority Data: 119069 14 August 1996 (14.08.96) IL		
(71) Applicants (<i>for all designated States except US</i>): MOR-RESEARCH APPLICATIONS LTD. [IL/IL]; Ben Gurion Street 11, 51905 Givat Shmuel (IL). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotinsky Street 46, 92182 Jerusalem (IL).		
(72) Inventors; and		
(75) Inventors/Applicants (<i>for US only</i>): NOVOGRODSKY, Abraham [IL/IL]; Shderot Chen 18, 76469 Rehovot (IL). LEV-ITZKI, Alexander [IL/IL]; Hapalmach Street 36, 96242 Jerusalem (IL). GAZIT, Aviv [IL/IL]; Nof Harim Street 14, 96190 Jerusalem (IL).		
(74) Agent: REINHOLD COHN AND PARTNERS; P.O. Box 4060, 61040 Tel Aviv (IL).		


(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING TYRPHOSTINS




(I)




(I)




(ii)




(iii)



(iv)



(v)



(vi)

(57) Abstract

Compounds useful for countering undesired toxic effects to cells, tissues or organs having formula (I) wherein: Ar is a group of formulae (i) or (ii), n is O or, when Ar has formula (i) above, then n may also be 1, R is CN, -C(S)NH₂, -C(O)NHR₃ or, when R₁ is 4-NO₂ and R₂ is H or 3-OH, then R may also be a group of formulae (iii), (iv), (v), (vi) where R₃ is H, phenyl, phenyl(lower alkyl) or pyridylmethyl; R₁ and R₂ are each independently H, OH, NO₂ or, when R is CN, also CH₃, F, or CF₃, provided that both R₁ and R₂ are not simultaneously H.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

- 1 -

PHARMACEUTICAL COMPOSITIONS COMPRISING TYRHOSTINS

FIELD OF THE INVENTION

The present invention concerns compositions which are useful to counter damage caused by harmful agents, particularly anti-neoplastic agents used in cancer treatment, e.g. cytotoxic drugs. Damage in the context of the 5 present invention means adverse effects on either cells, tissue or organs. The present invention also concerns therapeutic methods to counter such damage. Furthermore, the present invention concerns also novel compounds useful in such compositions and methods.

10 BACKGROUND OF THE INVENTION

Most of the commonly used antineoplastic treatments, including chemotherapy and radiation, have adverse toxic effects, manifested on dividing cells and in the function of certain organs. Cells which are particularly affected by such treatment are bone marrow cells, skin cells and 15 cells of the gastrointestinal tract epithelium. In addition, such treatments often cause damage to specific organs, such as the kidney and liver. As a result of such toxic effects, the therapeutic index of such treatments is limited.

It is a long felt want in medical research to try and develop 20 treatment modalities and means which will reduce the unwanted toxic side effects, without affecting the therapeutic activity of the drugs, thus increasing their therapeutic index.

- 2 -

Apoptosis or programmed cell death is a fundamental physiological mechanism of cell death regulated during embryonal development and normal homeostasis mechanisms within the body. Recent data indicated that the anti tumor effect of a variety of chemotherapeutic agents is related to their ability to induce apoptosis. The toxicity of these agents may also be related to the induction of apoptosis in normal cells.

Preliminary reports have described use of various pharmacological agents for the prevention of nephrotoxicity resulting from the use of anti-cancer drugs (Skinner, R., *Current Opinion in Oncology*, 7:310-315, 1995). Attempts were made to counteract the severe chronic proximal tubular toxicity resulting from use of the cytotoxic drug Cisplatin. In *in vivo* experiments in rats, para-aminobenzoic acid (PABA) co-administered together with cisplatin resulted in reduced nephrotoxicity of the cisplatin without reducing its anti-tumor activity. Other agents such as mitimazole, chloropromazin and L-arginine were also administered to animals in various *in vivo* experiments carried out in connection with toxicity of cisplatin resulting in only preliminary non-conclusive findings.

The drug amifostine which is dephosphorylated to yield a thiol moiety was also used for reducing anti-toxic effects of anti-neoplastic drugs (Cancer Res., 55:4069, 1995).

GENERAL DESCRIPTION OF THE INVENTION

The present invention provides, by a first of its aspects, a pharmaceutical composition for countering, i.e. reducing or preventing, damage to cells or tissue comprising, as an active agent, an effective amount of a compound of the general formula I:




- 3 -

wherinc:


- Ar is a group of the formulae

5



(i)

or




(I)

(ii)

- 10 - n is 0 or, when Ar has the formula (i) above, then n may also be 1,
 R is CN, -C(S)NH₂, -C(O)NHR₃ or, when R₁ is 4-NO₂ and R₂ is H or
 15 3-OH, then R may also be a group of the formula

15



- where R₃ is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
 - R₁ and R₂ are each independently H, OH, NO₂ or, when R is CN, also
 20 CH₃, F, or CF₃, provided that both R₁ and R₂ are not simultaneously H,
 together with a pharmaceutically acceptable carrier.

Said active agent and said pharmaceutical composition may be administered to or contacted with cells or tissue in a variety of conditions to reduce or prevent undesired damage to cells, tissues or organs. Examples of such conditions are such which may lead to apoptosis. Preventing of undesired apoptosis is a specific embodiment of the invention. Such conditions may also be exposure of said cells, tissue or organ to harmful factors, which may be exogenous or endogenous factors, as well as other physiological conditions, which may lead to damage, e.g. change in temperature, impairment of blood flow, exposure an ionizing irradiation, etc. The damage to be prevented may also be a result of natural physiological

deterioration processes, e.g. such occurring in cells, tissue or organs, maintained, grown or cultured *ex vivo*.

The present invention also provides a method of treatment of an individual, for countering damage to cells, tissue or organ, comprising
5 administering to the individual an effective amount of a compound having the general formula I.

The term "*effective amount*" should be understood as meaning an amount of the active compound, which is effective in countering damage manifested in either destruction of normal (non-diseased) cells or damage
10 to a tissue or organ.

The harmful factor may be an exogenous agent e.g., a therapeutic drug having a cytotoxic effect (e.g. anti-neoplastic drugs), irradiation, noxious chemicals, etc. In addition, the harmful factor may be endogenous, such as free radicals the level of which rises in the course of various
15 metabolic or other disorders, auto-antibodies, cytokines, etc.

The pharmaceutical compositions of the invention may be used in the framework of treatment of various diseases, disorders or conditions such as AIDS, conditions which may give rise to hepatotoxicity, radiation injuries, reducing or inhibiting damage to grafted cells or tissue as a result
20 of graft rejection, for the treatment of intoxications, e.g. paracetamol intoxication, for countering adverse effects of noxious solvents and carriers of therapeutic drugs, countering alcohol-caused damages, etc. Furthermore, the compositions may also be used for countering non-desired immune mediated reactions or an inflammatory response, e.g. septic shock, to reduce
25 damage caused by autoimmune reactions and others. Finally, the pharmaceutical compositions of the invention also may be used in *ex vivo* preservation of cells, tissues or organs used for transplantation to reduce or prevent cell or tissue deterioration or death which may otherwise occur during the time they are kept *ex vivo* prior to transplantation, etc.

30 The pharmaceutical compositions of the invention are especially useful to counter toxic effects of cytotoxic or anti-metabolic drugs, particularly such as used in cancer therapy. Occasionally, the pharmaceuti-

- 5 -


cal composition of the invention will be administered in conjunction with the cytotoxic drug. A pharmaceutical composition according to this embodiment may comprise such a drug in combination with a compound of above formula I.

5 The compounds of formula I belong to a family of compounds known as Tyrphostin compounds (Levitzki, A. and Gazit, A. *Science*, **267**:1782, 1995). In the following text, a compound of Formula I will be referred to as "*Tyrphostin*" and compositions comprising such compounds will at times be referred to as "*Tyrphostin compositions*".

10 Out of the tyrphostins of formula I, some are known, albeit for uses other than those provided by the invention, and others are novel. The novel tyrphostins, which constitute another, independent aspect of the invention, are those of formula I, wherein Ar, R₁ R₂ and R₃ are as defined above, with the provisos that

15

a) R cannot be



20 b) when R is CN and n is 0, then

(ba) if one of R₁ and R₂ is H or OH, then the other cannot represent NO₂;


(bb) if one of R₁ and R₂ is H or F, then the other cannot represent H or F; and

25 c) when R₁ is 4-NO₂, R₂ is H and n is 0, then R cannot represent -C(O)NH₂ or -C(S)NH₂.

Preferred compounds of formula I for use in the compositions are those wherein R is CN, -C(S)NH₂, -C(O)NHCH₂C₆H₅ or a group of the formula

30

- 6 -




5 and n is 0, R₁ is 4-NO₂ and R₂ is H.

Examples of tyrphostins are shown in compound Table I. Some of the tyrphostins shown in Compound Table I are novel, and these novel tyrphostins are shown also in Compound Table II.

10

- 7 -

Compound Table I









No.	R	R1	R2	m.p. °C	Ref. ¹
AG1714	CN	4 - NO ₂	H	153	1
AG1791		4 - NO ₂	H	238	2
AG1744		4 - NO ₂	H	277	3
AG1820		4 - NO ₂	H	103	-
AG1822		4 - NO ₂	H	220	-
AG1801		4 - NO ₂	H	161	-
AG1824		4 - NO ₂	H	236	-
AG1823		4 - NO ₂	H	187	-
AG1798		4 - NO ₂	H	98	-
AG1745		4 - NO ₂	H	148	-
AG1843		4 - NO ₂	H	-	-

¹ The numbers refer to the following attached list of references


- 8 -

Compound Table I (continued)

No.	R	R1	R2	m.p. °C	Ref.
AG126	CN 	4 - NO ₂	3 - OH	176	5
AG1719		4 - NO ₂	3 - OH	215	-
AG1720		4 - NO ₂	3 - OH	105	-
AG1759	CN	4 - NO ₂	3 - CH ₃	97	-
AG1762	CN 	4 - NO ₂	3 - F	120	-
AG1606		4 - NO ₂	3 - OH	148	-
AG1821		4 - NO ₂	3 - OH	178	6
AG1781	CN	3 - NO ₂	H	90	10
AG127	CN	3 - NO ₂	4 - OH	175	11
AG178	CN	4 - F	H	114	11,12
AG1754	CN	3 - F	4 - F	57	13
AG1755	CN	H	4 - CF ₃	95	-
AG1799	CN	4 - NO ₂	O ₂ S-C ₆ H ₄ -Cl	158	-

- 9 -

Compound Table II (Novel Compounds)



No.	R	R1	R2	m.p. °C
AG1822		4 - NO ₂	H	220
AG1801		4 - NO ₂	H	161
AG1824		4 - NO ₂	H	238
AG1823		4 - NO ₂	H	187
AG1798		4 - NO ₂	H	98
AG1745		4 - NO ₂	H	148
AG1843		4 - NO ₂	H	-
AG1719		4 - NO ₂	3 - OH	215
AG1720		4 - NO ₂	3 - OH	105
AG1759	CN	4 - NO ₂	3 - CH ₃	97
AG1762	CN	4 - NO ₂	3 - F	120
AG1606		4 - NO ₂	3 - OH	148
AG1755	CN	H	4 - CF ₃	95
AG1799	CN	4 - NO ₂	O ₂ S-C ₆ H ₄ -Ph	158

- 10 -

**List of References for several known compounds
used in accordance with the invention**

1. Mowry, D.T., *J. Am. Chem. Soc.*, **67**:1050, 1945
- 5 2. Zabichy, J., *J. Chem. Soc.*, 683, 1961.
3. Bronskill, J.S., De A., and Ewing, D.F., *J. Chem. Soc. Perkin Trans. I.*, 629, 1978
- 10 4. Junek, H., and Wolny, B., *Monat. Chem.*, **107**:999, 1976
5. Novogrodsky, A., Vanichkin, A., Patya, M., Gazit, A., Oshrov, N. and Levitzki, A., *Science*, **264**:1319, 1994
- 15 6. Sakamoto, M., *et al.*, *J. Chem. Soc. Perkin Trans I.*, 1759, 1995
7. (a) Flennner, A.L., C.A. **63**:13,278, 1965
20 (b) Lythgoe, K., Todd, A. and Tapham, C. *J. Chem. Soc.*, 515, 1944
8. Drabek, J. and Meyer, A., C.A., **89**:152,719, 1978
9. Gazit, A., *et al.*, *J. Med. Chem.*, **34**:1896, 1991
- 25 10. Carson, B.B., and Staughton, R.W., *J. Am. Chem. Soc.*, **50**:2825, 1928.
11. Gazit, A., *et al.*, *J. Med. Chem.*, **32**:2344, 1989
- 30 12. Weinberger, M.A., and Higgin, R.M., *Can. J. Chem.*, **43**:2585, 1965
13. Blox Ram, J., Dell, C.P., and Smith, C.W., *Heterocycles*, **38**:400, 1994.

35 Particularly preferred tyrphostins in accordance with the invention are the compounds designated as AG1714, AG1744, AG1801 and AG1843 in the above "*Compound Table I*". Out of these four compounds, the latter two are novel.

40 The tyrphostins of formula I may be administered to the patient in combination with another treatment, e.g. in combination with a cytotoxic drug or irradiation. In such a combination treatment the tyrphostins may be

- 11 -

administered simultaneously with or at a different time than the other treatment, so as to yield a maximum effect. A particular example is administration of the tyrphostins prior to the other treatment, e.g. several hours prior to the irradiation or to the administration of the cytotoxic drug.

It was found in accordance with the invention that when the tyrphostins of formula I are administered together with another therapeutic agent, they do not reduce the therapeutic activity of the other agent, but rather act in reducing its undesired toxic side effects to normal cells or tissue. This means that the therapy with the therapeutic agent will still achieve the same desired therapeutic effect, at the same dosage. For example, in the case of a chemotherapeutic drug, the administration of a tyrphostin will not, or may only minimally affect the effect of the drug in reducing the tumor load or preventing tumor growth or tumor recurrence, at a given administration dosage. In some cases, however, administration of the tyrphostins even intensifies the therapeutic effect of the treatment. The overall effect of the tyrphostins, in such a combination therapy, is thus the increase in the therapeutic index of another therapy, namely, increase in the ratio between the therapeutic effect of the therapy to its undesired toxic side effects. The increase in therapeutic index may at times be used to advantage of increasing the dosage of the therapeutic agent, e.g. the dosage of the cytotoxic agent or radiation, without a concurrent increase in undesired toxic side effects.

The tyrphostins according to the invention may be administered either in a single dose or may be given repetitively over a period of time, e.g. prior, during and after the treatment with a cytotoxic agent or irradiation.

A preferred mode of administration of the tyrphostins to humans is intravenously, although by a proper formulation, they may also be administered by other administration modes, e.g. intramuscularly, intraperitoneally or orally.

While the tyrphostin compositions will typically contain a single tyrphostin compound, it is possible at times to include in the composition

- 12 -

and or co-administer two or more tyrphostins which act together in a synergistic or additive manner to counter damages caused, e.g. by a therapeutic treatment.

5 BRIEF DESCRIPTION OF THE FIGURES

Fig. 1A is a graphic representation showing the mortality of mice treated with doxorubicin as compared to the mortality of mice receiving a single injection of AG1714 two hours before treatment with doxorubicin.

10 **Fig. 1B** is a graphic representation showing the mortality of mice treated with cisplatin as compared to the mortality of mice receiving a single injection of AG1714 two hours before treatment with cisplatin.

15 **Fig. 2** is a graphic representation showing the mortality of mice receiving 10 i.p. injections of doxorubicin (5 mg/kg) for a period of 21 days (cumulative dose 50 mg/kg) as compared to the mortality of mice treated as above but receiving an i.p. injection of AG1714 (5 mg/kg) two hours prior to each doxorubicin injection.

Fig. 3 is a graphic representation showing the mortality of mice treated with cisplatin alone or with cisplatin and AG1801 over a period of ten days after cisplatin administration.

20 **Fig. 4** is a graphic representation showing the mortality of mice treated with doxorubicin alone or with tyrphostins and doxorubicin over a period of ten days after doxorubicin administration.

25 **Fig. 5** is a graphic representation showing the effect of a number of tyrphostins on the toxic effect of cisplatin in kidneys of treated mice. The toxic effect is measured by the level of creatinine detected in the serum of the treated mice, a high level of creatinine indicating kidney damage (nephrotoxicity).

30 **Fig. 6** is a graphic representation showing the level of creatinine (Fig. 6A) and blood urea nitrogen (BUN) (Fig. 6B) (which are indicative of nephrotoxicity) in serum of mice receiving either cisplatin alone, AG1714 alone or a combination of cisplatin and AG1714. The levels of creatinine

- 13 -

and BUN were compared to the levels of the same substances in serums of control mice receiving the vehicle only.

Fig. 7 is a photograph showing histopathological analysis of kidneys (Fig. 7A-C) and small intestines (Fig. 7D-F) of mice administered with 5 cisplatin alone or with the tyrophostin AG1714 prior to the administration of cisplatin. Final magnification x 400:

Fig. 7A – kidneys of normal non-treated mice;

Fig. 7B – kidneys of mice receiving cisplatin alone showing large proteinaceous plaques in the proximal tubules;

10 **Fig. 7C** – kidneys of mice receiving AG1714 prior to cisplatin administration showing normal kidney structure;

Fig. 7D – small intestines of non-treated mice;

Fig. 7E – small intestine of mice receiving cisplatin alone showing severe necrosis and damage;

15 **Fig. 7F** – a small intestine of mice treated with AG1714 prior to cisplatin administration showing normal small intestine structure;

20 Fig. 8 is a graphic representation showing the level of two transaminases, Aspartic transaminase (AST) and Alanine-transaminase (ALT) in serum of mice receiving an injection of anti-FAS antibody alone or in combination with the tyrophostin AG1801. High levels of the 25 transaminases indicate anti-FAS antibody induced damage to the liver (hepatotoxicity);

Fig. 9 is a graphic representation showing the level of two transaminases AST and ALT in serum of mice receiving an injection of anti-FAS antibody alone or in combination with the tyrophostin AG1714; High levels of the transaminases indicate anti-FAS antibody induced damage to the liver (hepatotoxicity);

Fig. 10 is a graphic representation showing the level of AST and ALT in serum of mice treated with Con A alone or in combination with AG1714;

- 14 -

Fig. 11 is a graphic representation showing the level of AST and ALT in serum of mice treated with TNF/GaLN or in combination with the tyrophostin AG1714;

5 **Fig. 12** is a graphic representation showing the number of bone marrow nucleated cells (Fig. 12A) or the number of colony forming units (CFU) (Fig. 12B) in femur bone marrow of mice treated with doxorubicin alone, AG1714 alone or with their combination;

10 **Fig. 13** is a graphic representation showing the number of nucleated cells in bone marrow of mice treated with doxorubicin alone or with AG1714 and doxorubicin:

Fig. 13A shows the number of nucleated cells in bone marrow of the mice receiving different doses of doxorobucin;

Fig. 13B shows the number of nucleated cells in bone marrow of the treated mice at different periods of time after treatment with doxorubicin;

15 **Fig. 14** is a graphic representation showing the weight of the spleen (Fig. 14A) and thymus (Fig. 14B) of mice treated either with doxorubicin alone or with AG1714 prior to doxorubicin administration;

20 **Fig. 15** is a graphic representation showing the number of bone marrow nucleated cells in the femurs of mice treated with 5FU alone or with 5FU and AG1714;

Fig. 16 is a graphic representation showing the number of bone marrow nucleated cells in the femurs of mice treated with mitomycin-C alone or with mitomycin-C and AG1714;

25 **Fig. 17** is a graphic representation showing the number of nucleated cells in bone marrow of mice treated with doxorubicin alone or with AG1801 at different doses prior to doxorubicin administration;

Fig. 18 is a graphic representation showing the number of nucleated cells in bone marrow of irradiated mice (300R) and of mice treated with the tyrophostin AG1714 before irradiation;

- 15 -

Fig. 19 is a graphic representation showing the number of cells in bone marrow of irradiated mice (450R) and of mice treated with tyrphostin AG1714 before irradiation;

5 **Fig. 20** is a graphic representation showing the mortality of mice after lethal irradiation (800R) as compared to the mortality of mice treated with tyrphostin AG1714 prior to irradiation over a period of 23 days after irradiation;

10 **Fig. 21** is a graphic representation showing the weight of lungs of mice inoculated with MCA-105 fibrosarcoma cells (Fig. 21A), Lewis lung carcinoma cells (Fig. 21B) or B-16 melanoma cells (Fig. 21C) and treated with either cisplatin alone, AG1714 alone or with a combination of cisplatin and AG1714;

15 **Fig. 22** is a graphic representation showing the weight of nude mice bearing the SK-28 human melanoma tumors and treated with doxorubicin, AG1714 or their combination;

Fig. 23 is a graphic representation showing the volume of the human ovary carcinoma tumor (OVCAR-3) in mice treated either with cisplatin alone, with AG1714 alone or with their combination;

20 **Fig. 24** is a graphic representation showing the volume of the OVCAR-3 tumor in mice receiving repetitive administration of the treatments described in Fig. 23 above;

25 **Fig. 25** is a graphic representation showing the weight of lungs in MCA-105 fibrosarcoma tumor bearing mice treated with cisplatin alone, AG1801 alone or a combination of both (Fig. 25A) or with doxorubicin alone, AG1801 alone or their combination (Fig. 25B);

Fig. 26 is a graphic representation showing the weight of lungs of mice treated with cisplatin alone, AG1801 alone or a combination of both;

30 **Fig. 27** is a graphic representation showing the number of colony forming units (CFU) in cultures of bone marrow cells grown with or without various concentrations of AG1714;

- 16 -

Fig. 28 is a graphic representation showing the viability of thymocytes grown with or without AG1714 at various periods of time after the addition of AG1714 to the cells;

5 **Fig. 29** is a graphic representation showing the number of beats per minute in cardiomyocyte cultures grown with or without AG1714 as an indication of the viability of the cells;

10 **Fig. 30** is a graphic representation showing the percent lysis measured by percent of specific ^{51}Cr release of target EL-4 cells by murine peritoneal exudate cytotoxic lymphocytes (PEL) in the presence or absence of AG1714.

Preparative Examples

The preparation of several of the above novel compounds is exemplified in the following preparative examples. In all the examples below, the new compounds were synthesized by knocvenagel condensation 15 of the aldehyde with malononitrile or the substituted amide.

Example 1 - AG1801:

0.45 g, 3 mM, p-nitro benzaldehyde, 0.61 g, 3.5 mM, N-(Cyano acetyl) benzyl amide (reference 9) and 50 mg β -alanine in 20 ml ethanol 20 were refluxed for 5 hours. Cooling and filtering gave 0.67 g, 73% yield, light yellow solid, mp-164°. NMR(CDCl_3) δ 8.44 (1H,S,vinylic), 8.35, 8.07 (4H,AB, $J_{AB}=8.8$ Hz), 7.35 (5H,m), 6.6(1H,br.t,NH), 4.63(2H,d, $J=5.8$ Hz).

MS-m/e 307(M^+ , 50%), 290($M-\text{HCN}$,63), 260($M-\text{H-NO}_2$,91), 201($M-\text{NHCH}_2\text{C}_6\text{H}_5$,15), 173 ($M-\text{CONHCH}_2\text{C}_6\text{H}_5$,13), 155(22), 127(21), 25 105(100).

Example 2 - AG1798:

0.4 g, 2.65mM, p-nitrobenzaldehyde, 0.57 g, 2.8 mM, N(cyano acetyl) 30 3-propyl phenyl amide (reference 9) and 40 mg β -alanine in 30 ml ethanol were refluxed for 4 hours. The solution was concentrated by evaporation, cooled and filtered to give 0.38 g, 43% yield, light-yellow solid, mp-98.

- 17 -

NMR (CDCl_3) δ 8.38(1H,S, vinyl), 8.35, 8.06(4H,ABq, $J_{\text{AB}}=8.6$ Hz), 7.3(5H,m), 3.50(2H, $J=8.0$ Hz), 2.74(2H,t, $J=8.0$ Hz), 2.0 (2H,quintet, $J=8.0$ Hz).

5 Example 3 – AG1719:

146 mg, 0.87 mM, 3-hydroxy 4-nitro benzaldehyde, 48 mg, 0.89 mM, malononitrile dimer and 20 mg β -alanine in 10 ml ethanol were refluxed for 1 hour. Evaporation, trituration with CH_2Cl_2 -hexane and filtering gave 190 mg, 78% yield, yellow solid, mp-105. NMR (acetone d_6) δ 8.32(1H,d, $J=8.6$ Hz), 8.20(1H,S,vinyl), 7.77(1H,d, $J=2.2$ Hz), 7.65(1H,dd, $J=8.6$, 2.2 Hz).
10

Example 4 – AG1762:

170 mg, 1mM, 3-fluoro 4-nitro benzaldehyde, 80 mg, 1.2 mM, malononitrile and 15 mg β -alanine were refluxed for 1 hour. Evaporation, 15 trituration with hexane and filtering gave 202 mg, 93% yield, pink solid, mp-120°. NMR (CDCl_3) δ 8.22(1H,m), 7.83(3H,m).

MS-m/e 217(M^+ ,100), 187($M-\text{NO}$,78), 171($M-\text{NO}_2$,19), 159($M-\text{NO}-\text{HCN}-\text{H}$,80), 151($M-\text{NO}_2-\text{HF}$,33), 144($M-\text{NO}_2-\text{HCN}$,71), 132(75), 124($M-\text{NO}_2-\text{HCN}-\text{HF}$,81).
20

Example 5 – AG1799:

0.4g, 2.65 mM, 4-nitro benzaldehyde, 0.51 g, 2.8 mM, phenyl sulphonyl acetonitrile and 40 mg β -alanine in 30 ml ethanol were refluxed for 4 hours. Cooling, filtering and washing with ethanol gave 0.68 g, 82% 25 yield, light yellow solid, mp-158°. NMR (CDCl_3) δ 8.36(2H,d, $J=8.6$ Hz), 8.31(1H,S, vinyl), 8.07(4H,m), 7.70(3H,m).

Examples of biological and therapeutic activities

The biological and therapeutic effect of some of the compounds 30 which may be used in the composition of the invention will now be exemplified in the following non-limiting examples with occasional reference to the annexed figures.

- 18 -

I. Reduction of mouse mortality caused by doxorubicin or cisplatin by tyrphostins

5 Example 6

6 weeks old female CD1 mice were divided into the following groups:

- i. Mice injected intraperitoneally (i.p.) with doxorubicin (20 mg/kg);
- 10 ii. Mice injected i.p. with cisplatin (14 mg/kg);
- iii. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) two hours prior to the doxorubicin; and
- iv. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) two hours prior to receiving the cisplatin.

As seen in Fig. 1, treatment of mice with AG1714 significantly reduced the mortality of the mice as compared to the mortality of mice receiving doxorubicin alone ($p \leq 0.001$) (Fig. 1A) or of mice receiving cisplatin alone ($p \leq 0.005$) (Fig. 1B).

Example 7

20 6 weeks old female CD1 mice were divided into the following two groups:

- i. Mice receiving 10 i.p. injections of doxorubicin at a concentration of 5 mg/kg per each injection over 21 days (cumulative dose of 50 mg/kg); and
- 25 ii. Mice receiving 10 i.p. injections of doxorubicin at 5 mg/kg over 21 days with the addition of a single i.p. injection of AG1714 (5 mg/kg) two hours prior to each doxorubicin injection.

Each group consisted of 10 mice and the % mortality in each group was tested as explained above.

30 As seen in Fig. 2, the mortality of the mice receiving injections of AG1714 prior to each administration of doxorubicin was significantly reduced as compared to the high mortality of the mice receiving doxorubicin treatment alone.

- 19 -

Example 8

Two groups of CD1 mice were injected with 14 mg/kg of cisplatin as described above. One group received a single i.p. injection of AG1801 at a low dose of 1 mg/kg two hours before receiving the cisplatin injection.

5 As seen in Fig. 2, all the mice in the group receiving cisplatin alone died within ten days of the injection. Against this, in the group of mice receiving a single injection of AG1801 at a low dose prior to the cisplatin injection, the % mortality was only 20%.

10 Example 9

CD1 mice were divided into the following five groups:

- i. Mice receiving a single i.p. injection of 20 mg/kg of doxorubicin;
- ii. Mice receiving a single i.p. injection of 20 mg/kg of AG1714 and two hours later an i.p. injection of 20 mg/kg of doxorubicin;
- 15 iii. Mice receiving a single i.p. injection of 20 mg/kg of AG1782 and two hours later an i.p. injection of 20 mg/kg of doxorubicin;
- iv. Mice receiving a single i.p. injection of 20 mg/kg of AG126 and two hours later an i.p. injection of 20 mg/kg of doxorubicin.

The % mortality in each of the above groups was determined by scoring the number of dead mice every day until 10 days after injection.

20 As seen in Fig. 10, in the group of mice receiving doxorubicin alone (i), 90% of the mice were dead within a week after injection. In the other groups of mice receiving the tyrphostins before the administration of doxorubicin, the % mortality was reduced to between 50% (iii) to only 25 10% (ii).

II. Reduction of the toxic effect of various harmful agents on organs (kidneys, liver, intestines, heart) of treated mice by tyrphostins

30

Example 10

Groups of CD1 mice, each comprising three mice, were injected i.p. with a dose of 14 mg/kg of cisplatin. The mice in each of the groups except

- 20 -

for one were injected with a single i.p. injection an tyrphostin at a dose of 10 mg/kg two hours prior to the injection of the cisplatin. In order to assess the toxic effect of cisplatin on the kidneys of the treated mice (nephrotoxicity), the level of creatinine was determined in the serum of each mouse four 5 days after administration of the cisplatin using a commercial kit by Sigma.

As seen in Fig. 5, the creatinine level of about 2 mg/dl detected in the serum of mice receiving cisplatin alone, indicates that there is about a 50% reduction in the kidney function of these mice. Against this, the level of creatinine measured in the serum of many of the mice receiving an 10 injection of an tyrphostin before the cisplatin injection, was lower than the creatinine levels in the serum of mice receiving cisplatin alone. This indicates that injection of the tyrphostins prior to the cisplatin injection reduces the toxic effect of cisplatin on kidney function. The reducing effect on the nephrotoxicity of cisplatin varied between the different tyrphostins. 15 For example, AG1824, AG1744, AG1751, AG1714, AG1823, AG1782, AG1801, markedly reduced the nephrotoxicity of cisplatin bringing the creatinine levels in the serum to those of control mice.

Example 11

20 CD1 female mice were injected either with cisplatin alone or with a single injection comprising either the tyrphostin AG1843 or AG1714 two hours before injection of cisplatin and the level of the creatinine in their serum was tested as explained above.

As seen in Table 1 below and in agreement with the results of 25 Example 10 above, cisplatin alone had a nephrotoxic effect on the mice as seen by their high serum creatinine levels (1.53). This toxic effect of cisplatin was significantly reduced (to between 0.45–0.70) by injecting the tyrphostins two hours before cisplatin injection. In this example, the effect 30 of tyrphostin AG1843 administered at a low dose (5 mg/kg) was more effective than the administration of a high dose (20 mg/kg) of the same tyrphostin.

Table 1

Groups	Creatinine mg/dl (mean ± SD)
Control (Cosolvent)	0.46 ± 0.01
Cisplatin 14 mg/kg i.p.	1.53 ± 0.04
AG1843 5 mg/kg i.p. (-2h) + Cisplatin	0.45 ± 0.06
AG1843 20 mg/kg (-2h) + Cisplatin	0.70 ± 0.14
AG1714 20 mg/kg (-2h) + Cisplatin	0.58 ± 0.06

Example 12

CD1 mice were injected (i.p.) with cisplatin (14 mg/kg) or first with AG1714 (10 mg/kg) and two hours after with cisplatin as explained above. 5 Mice in the control group received injections of the vehicle only (a stock solution of ethanol: chemaphore (50:50) diluted with saline). Four days after administration of the cisplatin, several parameters indicating nephrotoxicity and liver injury were measured in the serums of each of the mice 4 days after cisplatin administration. The parameters showing nephrotoxicity of 10 cisplatin were creatinine and blood urea nitrogen (BUN) and the parameters indicating damage to the liver were the hepatic transaminases alanine-transaminase (ALT) and aspartic transaminase (AST) measured by standard methods. Each group consisted of three mice and the results are shown as mean levels of the measured parameter ± SD.

15 As seen in Fig. 6, administration of cisplatin alone to the mice resulted in elevated levels of creatinine (Fig. 6A) and BUN (Fig. 6B). Table 2 below shows that the levels of ALT and AST were also elevated in these mice. These results indicate both nephrotoxicity as well as damage to the liver of the mice as a result of the administration of cisplatin. As seen in 20 Fig. 6 and Table 2, administration of AG1714 two hours before injection of the cisplatin, resulted in a reduced level of all four measured parameters to their normal level as measured in the control mice.

- 22 -

Table 2**Prevention of cisplatin - induced kidney and liver injury by AG1714**

Treatment	ALT u/L	AST u/L
Control (vehicle)	30±4.7	58±1.5
Cisplatin (14 mg/kg)	73.5±2.1	209±16.0
Cisplatin (14 mg/kg) +AG1714 (20 mg/kg)	36±3.6	70±14.0

Example 13

CD1 mice were injected with 14 mg/kg of cisplatin or first with a single i.p. injection of the tyrophostin AG1714 and two hours later an injection of 14 mg/kg of cisplatin. Histopathological analysis of the kidneys and small intestines of the non-treated and treated mice was performed using slices from formaline fixed tissues stained with hematoxylin eosin.

As seen in Fig. 7, kidneys of mice receiving cisplatin alone showed large proteinaceous plaques in the proximal tubals (7B) as well as the appearance of granular material in the columnar epithel. Against this, kidneys of the mice receiving AG1714 injection prior to the cisplatin administration (7C) showed no damage and their structure was similar to that of control mice (7A).

As also seen in Fig. 7, the small intestine of mice receiving cisplatin alone (7E) showed severe necrosis and disintegration of the columnar intestinal epithelial cells as compared to the small intestines of mice receiving AG1714 prior to the cisplatin administration (7F) which showed a normal structure similar to that seen in the small intestine of non-treated mice (7D).

Example 14

In order to test the protective effect of AG1714 against doxorubicin-induced cardiotoxicity, 7 day primary rat cardiomyocytes cultures were prepared according to a standard procedure (described in: *In vitro Toxicology, Model System and Methods*, Eds. C. McQueen, Telford Press New Jersey, 1990, pg. 163, Primary cultures of neonatal rat myocardial cells, and Kessler-Icekson, G., *J. Mol. Cell Cardiol.*, **20**:649-755, 1988).

The cardiomyocyte cultures were divided into the following four groups receiving:

- 10 i. Vehicle only (control);
- ii. AG1714 as a final concentration of 20 μM ;
- iii. Cells receiving doxorubicin at a concentration of 10 μM ; and
- iv. Cells receiving AG1714 at a final concentration of 20 μM followed one hour later by the addition of doxorubicin (10 μM).

15 The rate of beats of clusters of cardiomyocytes ("mini-hearts") was determined 24 hours after beginning of incubation.

As seen in Table 3, in the cell cultures incubated with doxorubicin alone, the number of beats per minute was significantly reduced to about 20% of that of the control cultures incubated with the vehicle only. Against 20 this, in cultures incubated with doxorubicin together with AG1714, the number of beats per minute was similar to the number of beats per minute in the control cultures. Similar results (not shown) were seen in the above cardiomyocyte cultures 16 hours and 40 hours after incubation. Thus, 25 incubation of the cultures with AG1714 one hour before the addition of doxorubicin prevented the cardiotoxic effect of doxorubicin on the cell cultures.

Table 3

**Protective effect of AG1714 against Doxorubicin –
induced cardiotoxicity, *in vitro***

5

10

Treatment	Cellular beating (beats/min)
Control (vehicle)	78±2.0
AG1714 (20 uM)	68±2.2
Doxorubicin (10 uM)	15±1.3
Doxorubicin +AG1714	62±2.6

15

Example 15

The FAS antigen is a cell surface protein belonging to the two factor/nerve growth factor receptor family and have been shown to mediate apoptosis (Itoh, N. *et al.*, *Cell*, **66**:233–243 (1991)). Intraperitoneal administration of an anti-FAS antibody into mice was shown to cause severe damage of the liver by apoptosis.

20

In order to test the effect of the tyrphostin AG1801 and AG1714 on the anti-FAS antibody induced hepatotoxicity, Balb/C mice were injected i.p. either with AG1801 (5 mg/kg) or with AG1714 (5 mg/kg) and two hours later with an i.p. injection of an anti-FAS antibody at a dose of 25 5 µg/mouse. Another group of mice received only an injection of anti-FAS antibody with no prior treatment with the tyrphostins. Five hours after injection of the anti-FAS antibody, the animals were sacrificed and the level of two transaminases AST and ALT in the serum of the sacrificed mice was determined: a high level of these transaminases indicating hepatotoxicity 30 (Ogasaware, J., *et al.*, *Nature*, **364**:806–809, 1993).

As seen in Figs. 8 and 9, the level of AST and ALT in the serum of mice treated with the anti-FAS antibody alone was very high indicating FAS antibody induced hepatotoxicity.

- 25 -

Against this, the level of the two transaminases AST and ALT in serum of mice which were treated with AG1801 (Fig. 8) or with AG1714 (Fig. 9) prior to the anti-FAS injection was significantly lower. Thus, administration of the tyrphostins to mice results in their protection against hepatotoxicity induced by the anti-FAS antibody.

Example 16

T-cell mediated hepatotoxicity is a complication of various disorders and diseases such as Hepatitis B virus infection. Such hepatotoxicity can be induced by injection of Conavalin A (Con A). The effect of AG1714 on Con A induced hepatotoxicity on mice was determined in the following way (see Tiegs, G. *et al.*, *J. Clin. Invest.*, **90**:196-203, 1992).

CD1 mice were divided into the following groups:

- i. Mice receiving injection of the vehicle only (control);
- ii. Mice receiving i.p. injection of AG1714 (10 mg/kg);
- iii. Mice receiving an i.v. injection of Con A (35 mg/mouse); and
- iv. Mice receiving an i.p. injection of AG1714 (10 mg/kg) and two hours later an i.v. injection of Con A (35 mg/mouse).

6 hours after injection of Con A to the mice, serum levels of the liver enzymes AST and ALT of the treated mice were determined as explained above. Increase of serum levels of these enzymes reflect liver injury.

As seen in Fig. 10, while administration of AG1714 alone had no effect on the mice, injection of Con A caused significant hepatotoxicity in the mice. Administration of AG1714 prior to Con A administration significantly reduced the Con A induced hepatotoxicity in these mice.

Example 17

It is today known that liver damage may be induced by various immune mechanisms such as cytokines as well as by a variety of other agents known to exert an apoptotic effect (e.g. alcohol or paracetemol). A model for such liver injury induced by apoptosis was developed in which the

- 26 -

hepatic damage is induced *in vivo* by the injection of galactosamine and TNF- α (see Leist, M., et al., *J. Immunol.*, **153**:1778-1788, 1994).

The effect of AG1714 on TNF-induced liver damage in mice was determined as follows.

- 5 Mice were divided into the following four groups:
- i. Mice receiving an injection of the vehicle alone;
 - ii. Mice receiving 1 i.p. injection of AG1714 (10 mg/kg);
 - iii. Mice receiving an i.v. injection of human TNF- α (0.25 μ g/mouse) in combination with galactosamine (GalN) (18
10 ml/mouse, i.p.); and
 - iv. Mice receiving the treatment of group iii above together with an injection of AG1714 (10 mg/kg) injected i.p. two hours prior to TNF/GalN injection. 7 hours after injection of the TNF/GalN, the serum levels of the liver enzymes AST and ALT in the serum
15 of the various treated mice was determined as described above.

As can be seen in Fig. 11, injection of AG1714 prior to the administration of TNF/GalN to the mice significantly reduced the hepatotoxicity induced by the TNF/GalN administration. The tyrphostins may therefore be useful in the reduction of liver damage induced by various immune
20 mechanisms.

III. Reduction of the toxic effect of various harmful agents on nucleated bone marrow cells (myelotoxicity) and lymphocytes (lymphotoxicity) by tyrphostins

25

Example 18

CD1 mice were divided into the following groups:

- i. Mice receiving an i.p. injection of doxorubicin (10 mg/kg) alone;
- ii. Mice receiving an i.p. injection of AG1714 (20 mg/kg) and two hours later an i.p. injection of doxorubicin (10 mg/kg); and
- iii. Mice receiving one injection of the vehicle and two hours later an i.p. injection of doxorubicin (10 mg/kg).

- 27 -

3 days later, the number of bone marrow nucleated cells and colony forming units (CFU) in the femurs of the treated mice was determined (Nikerich, D.A., et al., *J. Immunopharmacol.*, 8:299-313, 1986). Each group contained 3 mice and the results are expressed as a means \pm SD.

5 As seen in Fig. 12, injection of doxorubicin to mice resulted 3 days later in myelotoxicity as manifested by 47% reduction in the number of nucleated cells (Fig. 12A) and 55% reduction in CFU (Fig. 12B). Mice who were pretreated with AG1714 two hours prior to doxorubicin injection were fully protected against its myelotoxicity effects.

10

Example 19

The effect of AG1714 on myelotoxicity induced by doxorubicin at different doses was investigated. Mice were treated as described in Example 18 above. The number of femur nucleated bone marrow cells in 15 the treated mice was determined three days (Fig. 13A) and at various times (Fig. 13B) post doxorubicin administration.

As seen in Fig. 13A, administration of doxorubicin to mice at a concentration of 10 mg/kg and 15 mg/kg induced myelotoxicity in the treated mice. Pretreatment with AG1714 reduced the doxorubicin induced 20 myelotoxicity significantly.

As seen in Fig. 13B, pretreatment of mice administered with doxorubicin with AG1714, resulted also in a rapid recovery of bone marrow cells after doxorubicin administration. 5 days after treatment with doxorubicin (15 mg/kg) alone, the number of bone marrow cells in the 25 femurs of the treated mice was still significantly reduced. Pretreatment of the mice with AG1714 prior to the doxorubicin administration, fully reconstituted their bone marrow at that time.

Example 20

30 CD1 mice received either a single i.p. injection of doxorubicin (10 mg/kg) or first single i.p. injection of AG1714 (20 mg/kg) and two hours later, an i.p. injection of doxorubicin (10 mg/kg). 72 hours after

- 28 -

doxorubicin administration the mice were sacrificed and the weight of the spleen and thymus of the mice was determined as parameters of lymphotoxicity. Each experimental group consisted of three mice and the results are mean no. of cells \pm SD. As control, the mice received an injection of
5 the vehicle only instead of doxorubicin.

As seen in Fig. 14 below, the administration of doxorubicin alone caused a significant reduction in the weight of spleens (Fig. 14A) and thymuses (Fig. 14B) of the mice. This myelotoxic and lymphotoxic effect of doxorubicin was significantly reduced by the administration of AG1714
10 to the mice two hours before administration of the doxorubicin.

Example 21

CD1 mice were injected with a single i.p. injection of cyclophosphamide at a dose of 50 mg/kg and divided into the following groups:

- 15 i. Mice receiving a single i.p. injection of the vehicle only two hours before administration of the cyclophosphamide;
ii. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) two hours before cyclophosphamide;
iii. Mice receiving a single i.p. injection of AG1801 (2.5 mg/kg) two
20 hours before cyclophosphamide administration.

72 hours after cyclophosphamide administration the mice were sacrificed and the nucleated cells in the bone marrow, spleen and thymus of the mice were counted. Each experimental group consisted of three mice and the results shown are the mean number of cells in a group \pm SD.

25 As seen in Table 4A and B, administration of cyclophosphamide caused a significant reduction in the number of nucleated cells in the bone marrow, spleen and thymus indicating myelotoxic and lymphotoxic effect of cyclophosphamide. Administration of the tyrophostins AG1714 or AG1801 prior to the administration of cyclophosphamide, resulted in a
30 reduction in the myelotoxic and lymphotoxic effect of cyclophosphamide in the above three organs. The number of nucleated cells in these organs was higher than in organs of mice receiving cyclophosphamide alone although

- 29 -

the level of the nucleated cells in the bone marrow, spleen and thymus of the mice treated with the tyrophostins did not reach control level.

Table 4a and b
**AG1714 and AG1801 prevent Cyclophosphamide -
 induced myelotoxicity and lympholysis**

Treatment	Nucleated cells in bone marrow ($\times 10^6$)	Spleen (mg)			Thymus (mg)
	AG1714 (20 mg/kg)				
	-	+	-	+	-
Vehicle	17.3±1.33	17.9±1.1	109±20.0	112±11.3	75±4.0
Cyclophosphamide (50 mg/kg)	6.2±0.31	11.2±0.6	52±2.5	87±2.0	39±6.1

Treatment	Nucleated cells in bone marrow ($\times 10^6$)	Spleen (mg)			Thymus (mg)
	AG 1801 (2.5 mg/kg)				
	-	+	-	+	-
Vehicle	17.3± 1.33	18.6±1.0	109±20.0	97±1.5 ²	75±4.0
Cyclophosphamide (50 mg/kg)	6.2±0.31	10.9±0.9	52±2.5	69±0.58	39±6.1

Example 22

CD1 female mice were divided into the following groups:

- i. A control group receiving a single i.p. injection of the vehicle only (co-solvent: propylene carbonate-cremophor-saline);
- 5 ii. Mice receiving a single i.p. injection of 5-fluorouracil (5 FU) at a dose of 80 mg/kg;
- iii. Mice receiving a single i.p. injection of AG1714 at a dose of 10 20 mg/kg;
- iv. Mice receiving a single i.p. injection of AG1801 at a dose of 15 2.5 mg/kg;
- v. Mice receiving a single i.p. injection of AG1843 at a dose of 5 mg/kg;
- vi. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) and two hours later a single i.p. injection of 5 FU (80 mg/kg);
- vii. Mice receiving a single i.p. injection of AG1801 (2.5 mg/kg) and two hours later a single i.p. injection of 5 FU (80 mg/kg); and
- viii. Mice receiving a single i.p. injection of AG1843 (5 mg/kg) and two hours later a single i.p. injection of 5 FU (80 mg/kg).

Five days after the administration of 5 FU to the mice, the mice were 20 sacrificed and the number of nucleated cells in the bone marrow of one femur, were counted. Each group of mice consisted of two or three mice and the results shown are the mean number of cells counted \pm SD.

As seen in Fig. 15, administration of 5 FU to the mice resulted in a decrease in the number of nucleated cells in the bone marrow of these mice. 25 The administration of the AG1714 before 5 FU administration to the mice, resulted in a significantly lower reduction in the number of cells in the bone marrow. Thus the AG1714 reduced the myelotoxic effect of 5 FU in these mice.

- 32 -

Example 23

CD1 female mice were divided into the following groups:

- i. A control group receiving a single i.p. injection of the vehicle only (co-solvent: propylene carbonate-cremophor-saline);
- 5 ii. Mice receiving a single i.p. injection of mitomycin-C at a dose of 2 mg/kg;
- iii. Mice receiving a single i.p. injection of AG1714 at a dose of 20 mg/kg;
- 10 iv. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) and two hours later a single i.p. injection of mitomycin-C (2 mg/kg);

As described in Example 22 above, five days after the administration of mitomycin-C to the mice, the mice were sacrificed and the number of nucleated cells in the bone marrow of one femur, were counted. Each group of mice consisted of two or three mice and the results shown are the mean 15 number of cells counted \pm SD.

As seen in Fig. 16, mice receiving mitomycin-C alone showed a very low count of nucleated cells in their bone marrow. While administration of AG1714 alone had no effect on the mice, its administration prior to the administration of mitomycin-C to the mice resulted in a reduction in the 20 myelotoxic effect of the mitomycin-C in these mice and provided almost full protection from the harmful effects of the mitomycin-C bringing the nucleated cell count in the bone marrow of these mice to the level of control mice receiving the cosolvent only.

25 Example 24

The effect of various doses of AG1801 against doxorubicin induced myelotoxicity in mice was determined. CD1 mice were divided into five groups:

- i. Mice receiving the vehicle alone;
- 30 ii. Mice receiving doxorubicin (10 mg/kg) alone;
- iii. Mice receiving an i.p. injection of AG1801 (0.5 mg/kg) two hours prior to doxorubicin administration;

- iv. Mice receiving an i.p. injection of AG1801 (1 mg/kg) two hours prior to doxorubicin administration; and
- v. Mice receiving an i.p. injection of AG1801 (2 mg/kg) two hours prior to doxorubicin administration.

5 Three days after doxorubicin administration, the mice were sacrificed and the number of nucleated cells in bone marrow was determined as described above.

10 As seen in Fig. 17, administration of AG1801 to the mice had a protective effect against doxorubicin induced myelotoxicity which was dose dependent.

IV Reduction of radiation-induced toxicity by tyrphostins

Example 25

15 In order to test the protective activity of the tyrphostin AG1714 in radiated mice, CD1 mice irradiated with a radiation dose of 300R using a cobalt source were divided into two groups:

- i. Mice receiving no further treatment; and
- ii. Mice receiving a single i.p. injection of the tyrphostin AG1714 at a dose of 20 mg/kg two hours before irradiation.

20 A third group of mice received only a single injection of AG1714 (20 mg/kg) and a fourth group of mice served as control mice which were not treated.

At different periods of time after irradiation, mice were sacrificed and the number of cells in the bone marrow of one femur were counted.

25 As seen in Fig. 18, irradiation of the mice with 300R caused a decrease in the number of cells in the bone marrow of these mice as compared to untreated mice or mice treated only with AG1714. Reconstitution of cells in the bone marrow of the irradiated mice began about five days after their radiation. Treatment of the irradiated mice with AG1714 prevented the 30 decrease in the number of cells in the bone marrow of the irradiated mice and caused a very significant enhancement of the number of cells in their

bone marrow. Thus, the tyrphostin AG1714 has a protective effect against myelotoxicity caused by irradiation.

Example 26

5 The protective effect of the tyrphostin AG1714 against myelotoxicity caused by a high dose irradiation (450R) was tested as described in Example 25 above except that the dose of irradiation was 450R instead of 300R.

10 As seen in Fig. 19, the number of cells in the bone marrow of mice irradiated with 450R was significantly reduced five days after radiation indicating a severe myelotoxic effect of the irradiation on these mice. Five days after irradiation reconstitution of the number of cells in the bone marrow began but 18 days after radiation, the number of cells in the bone marrow of the irradiated mice still remained significantly lower than the number of cells in the bone marrow of non-treated mice or mice receiving 15 AG1714 alone. In the bone marrow of mice receiving AG1714 before their irradiation, myelotoxic effect was also seen until five days after radiation. However, after five days, a significant reconstitution was seen in the number of cells in the bone marrow of these mice and 18 days after irradiation, the number of cells in the bone marrow of the irradiated mice receiving 20 AG1714 was higher than the number of cells in the control mice. Administration of AG1714 thus enhance the reconstitution of the number of cells in the bone marrow of mice irradiated by high dose irradiation.

Example 27

25 CD1 mice were irradiated with a lethal 800R dose using a cobalt source, and divided into two groups:

- i. Mice receiving irradiation only; and
- ii. Mice receiving a single i.p. injection of AG1714 at a dose of 20 mg/kg one hour before irradiation.

30 Each group of mice consisted of 10 mice and the % mortality in each group was tested by scoring the number of dead mice each day after irradiation.

- 35 -

As seen in Fig. 20, in the group of mice receiving an 800R irradiation, mortality of the mice began 10 days after irradiation and the % mortality in this group reached the rate of 80% 23 days after their irradiation. Against this, the % mortality in the group of mice receiving AG1714 before their 5 irradiation was significantly reduced to 20% mortality 20 days after irradiation.

The mortality in both groups did not change further until 50 days after irradiation.

10 **V. The effect of tyrphostins on anti-tumor activity of chemotherapeutic agents**

Example 28

15 The effect of AG1714 on the anti-tumor effect of chemotherapy was determined using a variety of experimental tumor models in mice.

2×10^5 /mouse MCA-105 fibrosarcoma cells or Lewis Lung carcinoma cells and 5×10^4 /mouse B-16 melanoma cells were injected into the tail vein of C57BL mice.

20 Cisplatin (4 mg/kg) was injected i.p. 4 days after tumor inoculation. AG1714 (20 mg/kg) or vehicle was injected i.p. 2 hours prior to cisplatin. Twenty-four days after tumor inoculation, mice were sacrificed, lungs weighed and the number of metastases were scored. Each group contained 5 mice and the results are expressed as the means lungs' weights \pm SE.

25 As seen in Fig. 21A, cisplatin markedly inhibited the growth of MCA-105 fibrosarcoma. AG1714 by itself had a small anti-tumor effect. Combined treatment with AG1714 and cisplatin was as effective as cisplatin alone, in suppression of the growth of the established lung metastases of MCA-105. Cisplatin and AG1714 by themselves had a partial anti-tumor effect against Lewis lung carcinoma. Combined treatment with AG1714 and 30 cisplatin was more effective than cisplatin also in suppression of the growth of established lung metastases of this tumor (Fig. 21B).

Cisplatin (4 mg/kg) or AG1714 (20 mg/kg) alone were not effective against established lung metastases of B-16 melanoma (Fig. 21C).

- 36 -

Combined treatment with these agents was more effective than treatment with each agent alone.

Example 29

5 The effect of doxorubicin and AG1714 on SK-28 human melanoma tumor xenografts in nude mice was determined as follows:

CD1 athymic mice (nu/nu) were inoculated i.v. with 4×10^5 /mouse SK-28 human melanoma. Doxorubicin (4 mg/kg) was injected i.p. 4 days after tumor inoculation. AG1714 (20 mg/kg) or vehicle were injected 2 10 hours prior to doxorubicin. The weights of the treated mice lungs and number of metastases in the lungs were determined 24 days after tumor inoculation. Each group contained 5 mice and the results are expressed as means \pm SE.

As seen in Fig. 22, doxorubicin markedly suppressed the growth of the 15 SK-28 tumor whereas AG1714 by itself had a small anti-tumor effect. Pretreatment with AG1714 did not impair the effect of doxorubicin alone in the suppression of the growth of this tumor.

Example 30

20 Athymic mice were inoculated subcutaneously (s.c.) with human ovary carcinoma (OVCAR-3) cells (3×10^6 cells/site). Cisplatin (4 mg/kg) was injected 4 days after tumor inoculation. AG1714 (20 mg/kg) or vehicle was injected i.p. 2 hours prior to cisplatin. Twenty days post tumor inoculation the short (S) and long (L) diameters of the tumor were measured and the 25 tumor volume (V) was calculated according to the formula: $V = \frac{S^2 \times L}{2}$.

Each group contained 5 mice and the results are expressed as the means \pm SE.

As seen in Fig. 23, cisplatin had a marked anti-tumor effect in the mouse bearing OVCAR-3 tumors whereas AG1714 itself was less effective.

Administration of AG1714 did not impair the chemotherapeutic effect of cisplatin.

As seen in Fig. 24, the difference in the diameter of the tumor volume of tumors in mice receiving repeated injections of cisplatin and AG1714 as compared to the volume of tumors in mice receiving repeated injections of cisplatin alone or repeated injections of AG1714 alone.

Example 31

The effect of AG1714 on high dose doxorubicin efficacy was measured by determining the mortality of B-16 melanoma bearing mice and the number of metastases in their lungs or the lung weight.

Mice were injected i.v. with 2×10^5 B-16 melanoma cells and 4 days after tumor inoculation each mouse received a single i.p. injection of doxorubicin (4 mg/kg or 8 mg/kg). Two hours prior to the doxorubicin injection, each mouse was injected i.p. with AG1714 at a dose of 20 mg/kg.

As seen in Table 5A and B showing two experiments carried out as explained above, administration of low dose doxorubicin resulted in low mortality of the mice and in a significant therapeutic effect. High dose administration of doxorubicin resulted in a much more significant therapeutic effect but resulted in a high mortality rate of the treated mice. AG1714 administered alone showed some therapeutic effect in itself. The combined administration of doxorubicin at a high dose together with AG1714 resulted in the high therapeutic effect of the high doxorubicin, however, the mortality of the mice were significantly reduced.

- 38 -

Table 5**Effect of AG1714 on high dose doxorubicin efficacy and mortality in B-16 melanoma bearing mice****A.**

Treatment	No. of lungs' metastases (+SD)	Mortality (dead/total)
Vehicle	29 ± 9	0/4
AG1714 (20 mg/kg)	16 ± 5	0/4
Doxorubicin (4 mg/kg)	7 ± 4	0/4
Doxorubicin (4 mg/kg) + AG1714 (20 mg/kg)	7 ± 6	0/4
Doxorubicin (8 mg/kg)	1	3/4 (75%)
Doxorubicin (8 mg/kg) + AG1714 (20 mg/kg)	2 ± 1	0/4
No tumor	-	0/4

B.

Treatment	Lungs' weight (mg+SEM)	Mortality (dead/total)
Vehicle	976 ± 142	0/6
AG1714 (20 mg/kg)	870 ± 178	0/6
Doxorubicin (4 mg/kg)	306 ± 12	0/6
Doxorubicin (4 mg/kg) + AG1714 (20 mg/kg)	303 ± 28	0/6
Doxorubicin (8 mg/kg)	-	7/8 (88%)
Doxorubicin (8 mg/kg) + AG1714 (20 mg/kg)	246 ± 10	2/8 (25%)
No tumor	232 ± 12	0/3

Thus the combined administration of AG1714 together with doxorubicin resulted in the intensification of the chemotherapeutic effect of doxorubicin. The significant therapeutic effect of the high dose doxorubicin administered with AG1714 could be achieved while the high mortality rate

- 39 -

of the high dose doxorubicin was neutralized by the combined administration.

Such an intensification effect could also be seen in mice bearing MCA-105 fibrosarcoma tumors and treated with either doxorubicin alone 5 (Table 6A) or cisplatin alone (Table 6B) or with a combination of each of the above with AG1714.

Table 6

Effect of AG1714 on high dose doxorubicin efficacy and mortality in MCA-105 fibrosarcoma bearing mice

A.

Treatment	Lungs' weight (mg+SEM)	Mortality (dead/total)
Vehicle	908 ± 107	0/8
AG1714 (20 mg/kg)	632 ± 74	0/6
Doxorubicin (4 mg/kg)	47 ± 119	0/5
Doxorubicin (4 mg/kg) + AG1714 (20 mg/kg)	494 ± 137	0/5
Doxorubicin (8 mg/kg)	170 ± 4	5/8 (62.5%)
Doxorubicin (8 mg/kg) + AG1714 (20 mg/kg)	172 ± 6	2/8 (25%)
No tumor	161 ± 12	0/4

- 40 -

B.

Treatment	Lungs' weight (mg+SEM)	Mortality (dead/total)
Vehicle	982 ± 102	0/6
AG1714 (20 mg/kg)	656 ± 127	0/6
Doxorubicin (4 mg/kg)	420 ± 69	0/6
Doxorubicin (4 mg/kg) + AG1714 (20 mg/kg)	216 ± 33	0/6
Doxorubicin (8 mg/kg)	186 ± 16	5/7 (71%)
Doxorubicin (8 mg/kg) + AG1714 (20 mg/kg)	167 ± 5	2/6 (33%)
No tumor	161 ± 6	0/6

Example 32

The effect of AG1801 on the anti-metastatic activity of cisplatin on established lung metastases of MCA-105 fibrosarcoma bearing mice was determined as follows:

- 5 C57BL mice were divided into the following groups:
- i. Mice injected i.v. at the age of 6 weeks with 2×10^5 fibrosarcoma MCA105 cells and 4 days' later, receiving an injection comprising the vehicle only;
 - 10 ii. Mice injected i.v. at the age of 6 weeks with 2×10^5 fibrosarcoma MCA105 cells and 4 days' later, injected with 10 mg/kg of cisplatin;
 - 15 iii. Mice injected i.v. at the age of 6 weeks with 2×10^5 fibrosarcoma MCA105 cells and 4 days' later, injected with 10 mg/kg of doxorubicin;
 - iv. Mice injected i.v. at the age of 6 weeks with 2×10^5 fibrosarcoma MCA105 cells and 4 days' later, injected with 5 mg/kg of AG1801;

- 41 -

- v. Mice injected i.v. at the age of 6 weeks with 2×10^5 fibrosarcoma MCA-105 cells and 4 days' later, injected with 5 mg/kg of AG1801 and 2 hours' later, with 10 mg/kg of cisplatin;
- 5 vi. Mice injected i.v. at the age of 6 weeks with 2×10^5 fibrosarcoma MCA-105 cells and 4 days' later, injected with 5 mg/kg of AG1801 and 2 hours' later, with 10 mg/kg of doxorubicin; and
- vii. Non treated C57BL mice.

As seen in Fig. 25A and 25B, the weight of the lungs of the tumor bearing mice were significantly higher than that of the control mice. While 10 injection of AG1801 alone had no affect, the injection of cisplatin (Fig. 25A) or doxorubicin (Fig. 25B) reduced the weight of the mice's lungs to a weight similar to that of control non tumor bearing mice. The combined injection of cisplatin and AG1801 (Fig. 25A) and the combined injection of doxorubicin and AG1801 (Fig. 25B) resulted in reduction of 15 tumor load in the lungs of the mice similar to the reduction in the tumor load of mice receiving the cisplatin alone.

The results of the above four examples clearly show that administration of tyrphostins to tumor bearing mice together with cisplatin 20 does not affect the antitumor affect of the cisplatin and in some cases even increases it.

Example 33

The effect of cisplatin and AG1801 on SK-28 human melanoma tumor 25 xenografts in nude mice was determined as explained in Example 29 above.

As seen in Fig. 26, the administration of cisplatin alone reduced the weight of the lungs of the tumor bearing mice to an extent while administration of AG1801 had no therapeutic effect in itself. Combined administration of AG1801 with cisplatin significantly reduced the rate of lungs of the 30 treated mice and thus the administration of AG1801 prior to cisplatin administration enhanced its therapeutic effect.

The above examples clearly show that administration of tyrphostins to tumor bearing mice together with cisplatin or doxorubicin does not impair the anti-tumor effect of the therapeutic agents and in some cases even increases it. Therefore the tyrphostins could be useful in potentiating and 5 intensifying the chemotherapeutic effect of such agents.

VI. The effect of AG1714 on the viability of various cells *in vitro* was determined as follows:

10 Example 34

Murine bone marrow nucleated cells were prepared by gradient centrifugation on histopaque. The cells were then divided into two groups:

- 15 i. Cells incubated for one hour in growth medium alone (control);
ii. Cells incubated for one hour in growth medium with the addition of various concentrations ($5 \mu\text{M}$; $10 \mu\text{M}$ or $20 \mu\text{M}$) of the tyrphostin AG1714.

Cells were then plated on semi-solid agar and the number of colony forming units (CFU) was determined after a 14 day incubation period (see: Nikerich *et al.*, *supra*, 1986).

20 As seen in Fig. 27, the plating efficiency (determined by the number of CFU per 10^5 nucleated cells) of the cultures to which AG1714 was added was significantly enhanced as compared to that of the cells grown in growth medium alone. Thus, the tyrphostin AG1714 enables longer preservation of bone marrow cell culture.

25

Example 35

Thymocytes were prepared from thymuses of young CD1 mice at a concentration of 3×10^6 cell/ml in RPNI1640 growth medium containing 5% FCS. The cells were divided into two groups:

- 30 i. Cells grown in the presence of growth medium alone; and
ii. Cells grown in growth medium with the addition of AG1714.

- 43 -

The cell viability of the thymocytes in each of the above cultures was determined using the trypsin blue exclusion test at various periods of time after the addition of AG1714 to the cells.

As seen in Fig. 28, addition of AG1714 to the thymocytes in culture 5 significantly enhanced their viability.

Example 36

Primary rat myocyte cultures were prepared from rats as described in Kessler-Iceksan, G., *J. Mol. Cell. Cardiol.*, **20**:649-755, 1988. 10 Cardiomyocytes were grown in culture for seven days and then the cultures were divided into two groups:

- i. Cultures grown in growth culture alone;
- ii. Cultures grown in growth culture with the addition of 20 μ M of the tyrphostin AG 1714.

15 The number of beats per minute of the myocyte clusters in each culture was determined 16 hours and 40 hours after the addition of the tyrphostins to the cells.

As seen in Fig. 29, the number of beats per minute in the cardiomyocyte cultures to which the tyrphostin AG1714 was added were 20 significantly higher than the number of beats per minute in the cultures grown in the growth medium alone. AG1714 enhanced the viability of the cardiomyocytes in culture.

VII. Toxicity study of tyrphostins

Example 37

In order to study the toxic effects of the tyrphostins AG1714 and AG1801, the tyrphostins were injected to ICR mice 3 times a week over a period of five weeks. Each injection contains 20 mls. of the tyrphostins which was prepared in the vehicle propylene carbonate:cremophore (40/60) 30 diluted 1:20 with saline/bicarbonate.

In order to test the toxic effect of the cumulative administration of the tyrphostins, various parameters of the injected mice were determined

- 44 -

including their weight, weight of their internal organs (thymus, spleen, kidney), full blood chemistry, number of bone marrow cells, etc.

As seen in Table 7 below, injection of the tyrphostins AG1714 and AG1801 caused no significant changes in the parameters tested in the injected mice as compared to the same parameters in control mice injected with saline or the vehicle only. Therefore, no toxic effects of the tyrphostins were apparent following their cumulative administration to mice. In addition, injection of the tyrphostins caused no mortality of the mice.

- 45 -

Table 7

**Subchronic intraperitoneal administration of
AG1714 and AG1801**

(ICR female mice, injection 3 times a week, 5 weeks)

	Control 1 Saline	Control 2 Vehicle	AG1714 20 mg/kg x 15	Ag1801 5 mg/kg x 15
Weight (g)		29.3±3.1	28.6±2.3	29.1±1.7
Thymus (mg)		50.2±7.7	53.8±12.3	57±9.3
Spleen (mg)		118±27	136±16	119±19.6
Kidney (mg)		176±21	162±12	164±9.8
Leukoc. (k/uL)	6.1±2.3	5.5±0.98	4.9±2.3	6.8±3.3
Lymph. (%)	88.1±2.35	83.3±4.12	81.5±2.35	80.4±6.1
Neutr. (%)		4.2±1.4	4.2±1.2	5.3±1.2
Monoc. (%)		10.6±2.6	11.9±1.3	12.3±5.2
Eosin. (%)		0.2±0.1	0.1±0.05	0.3±0.23
Basoph. (%)		0.22±0.08	0.24±0.11	0.3±0.07
RBC (M/uL)		8.4±0.33	9.0±0.33	8.4±0.3
HGB (g/dL)	14.0±2.5	14.2±0.5	14.9±0.56	14.5±0.67
PLT (K/uL)	1236±176	1229±12.7	1475±252	1309±304
Glucose (mg/dL)	147±11.3	177±24	144±17	177±20.5
BUN (mg/dL)	22±4.4	21±2.9	25.2±3.3	24.2±2.2
Creatinine (mg/dL)	0.4±0.0	0.42±0.04	0.46±0.05	0.42±0.04
Total Prot. (g/dL)	5.4±0.17	5.6±0.2	5.8±0.2	5.6±0.08
Albumin (g/dL)	3.1±0.0	3.1±0.09	3.2±0.13	3.1±0.07
Calcium (mg/dL)	9.9±0.4	9.9±0.26	9.9±0.3	9.8±0.36
In. Phosph. (mg/dL)	8.5±0.7	8.0±0.75	8.4±0.43	7.9±1.1
Uric acid (mg/dL)	1.1±0.21	2.0±0.44	1.8±0.18	2.0±0.36

Table 7 continued

	Control 1 Saline	Control 2 Vehicle	AG1714 20 mg/kg x 15	Ag1801 5 mg/kg x 15
Total Bilirub. (mg/dl)	0.23±0.06	0.2±0.0	0.2±0.0	0.2±0.0
Alk. Phosph. (U/l)	110±23.8	79±17	67±12.8	69.6±0.26
LHD (U/l)	545±157	996±235	960±226	972±238
GOT (U/l)	67±11	71.4±6.5	70±18	68±12
GPT (U/l)	30±4.6	28.8±3.1	25.6±4.2	28±5.5
CPK (U/l)	461±179	604±115	659±486	582±127
Amylase (U/l)	2451±176	2211±352	2392±230	2169±222
Cholester. (mg/dl)	115±25	98.8±17.5	99±5.7	90±6.1
Triglycer. (mg/dl)	216±84	125±17.9	155±54	138±50
Nuclear BM cells x 10 ⁶	16.3±0.7	15.2±2.0	18.6±3.6	16.5±0.87
Colonies (in femur)		12790±1620	17600±2590	15690±2040
Clusters (in femur)		8170±697	15000±2140	13410±1740

Vehicle – Propylene carbonate: Cremophore (40:60)
Diluted 1:20 with saline/bicarbonate

VIII. Inhibition of immune specific activities

Example 38

Murine peritoneal exudate cytotoxic lymphocytes (PEL) capable of specific lysis of EL-4 cells were prepared and tested as described in Lavy, R. *et al.*, *J. Immunol.* **154**:5039–5048, 1995. The EL-4 cells were divided into cells which were incubated with PELs alone, cells which were incubated with AG1714 (20 µM) and then with PELs and cells which were incubated with AG1714 (50 µM) and then with PELs. The lysis of the target EL-4 cells was determined using the specific ⁵¹Cr release assay.

As seen in Fig. 30, addition of AG1714 reduced the specific cytotoxic activity of PELs against the target EL-4 cells. The inhibitive effect of AG1714 was dose dependent.

The above results indicate that tyrphostins may be useful for reducing immune mediated rejection of transplants, in cases of autoimmunity and in conditions involving specific immune activity against cells (e.g. anti-CD4 cells such as in the case of AIDS).

5

IX. Anti-inflammatory effect of tyrphostins

One of the main complications of an inflammatory reaction in an individual is the development of septic shock which results from over effects of the immune reaction which is mediated mainly by cytokines such as TNF 10 and IL-1. The involvement of tyrphostins in TNF and IL-1 related immune responses was determined as follows:

Example 39

A. Incubation of mouse fibroblastic cells with TNF- α result in apoptosis 15 of these cells. In order to test the effect of tyrphostins on the TNF- α -induced apoptosis of the cells, A9 mouse fibroblastic cells were incubated for two hours with cycloheximide (50 μ g/ml) after which the various tyrphostins were added at a final concentration of 20 μ M except AG1801 that was added at the final concentration of 5 μ M. Following one 20 hour incubation with the tyrphostins, TNF- α was added to the cells at a concentration of 0.2 ng/ml and the cells were incubated for an additional ten hours. At the end of ten hours, the cell cultures were analyzed by FACS 25 using propidium iodide and the extent of apoptosis in each of the cell cultures (seen as DNA fragmentation) was determined (see Novogrodsky, A., *et al.*, *Science*, **264**:1319-1322, 1994).

As seen in Table 8 below, addition of the various tyrphostins to the mouse fibroblastic cells incubated with TNF, reduced the apoptotic effect of TNF significantly. The extent of the reduction of the apoptotic effect of TNF by the various tyrphostins was slightly different.

- 48 -

Table 8

**Prevention of TNF- α - induced apoptosis
of mouse fibroblastic cells (A-9) by tyrphostins**

Tyrphostins*	Apoptosis (%)	
	TNF- α (0.2 ng/ml)	
	-	+
None (vehicle)	9.3	28.7
AG1714	4.5	9.9
AG1801	6.6	10.2
AG126	8.3	19.4
AG1802	7.6	17.2

* All tyrphostins were added at a final concentration of 20 μ M, except AG1801, that was added at a final concentration of 5 μ M

B. As seen in Table 9, cell cycle analysis of the above cell cultures showed that treatment of the cells with TNF- α induced a G₁ arrest. There was a direct correlation between the tyrphostins' reduction of the apoptotic effect caused by TNF and their ability to prevent G₁ arrest in the cell cultures.

Table 9

**Prevention by AG1714 of TNF- α - induced G₀/G₁ arrest
and apoptosis in mouse fibroblastic cells (A-9)**

	Cell cycle			Apoptosis
	G1	S	G2+M	
	%	%	%	
Control	60.8	36.2	3.0	9.3
TNF- α (0.2 ng/ml)	85.8	7.6	6.6	28.7
AG1714 (30 μ M)	58.1	38.1	3.8	4.5
TNF- α + AG1714	64.5	31.2	4.3	9.9

Example 40

The effect of tyrphostins on TNF-induced cytotoxicity was determined *in vitro* using A-9 cells as described in Example 39 above. In addition, the effect of tyrphostin on TNF mediated cytotoxicity *in vivo* was determined 5 in mice injected with LPS (which induces TNF toxicity *in vivo*). *E.coli* LPS the concentration of 1.3 mg/mouse was injected i.p. to CD1 mice. While control mice were injected in addition with the vehicle only, the remaining mice were injected with the various tyrphostins (20 mg/kg) i.p. 10 two hours prior to LPS injection. As seen in Table 10A, in agreement with the results shown in Example 39 above, addition of tyrphostins to the cells incubated with TNF significantly reduces the cytotoxic effect of TNF. As seen in Table 10B, most of the tyrphostins showed a significant protective effect against the LPS-induced toxicity *in vivo* which correlated with their activity *in vitro*.

15

Table 10**Effect of tyrphostins on TNF – induced cytotoxicity (*in vitro*)
and LPS – induced lethal toxicity (*in vivo*)****A**

		<i>in vitro</i> , (live cells, % of control)			TNF
AG (20 µM)	None	0.05 ng/ml	0.2 ng/ml	1.0 ng/ml	
Control	100	41	19	6	
AG1714	119	102	90	62	
AG1719	102	83	58	41	
AG26	107	86	64	31	
AG126	107	75	49	33	
AG1641	102	70	41	21	
AG1720	104	53	26	11	

- 50 -

B

<i>in vivo</i>	
alive/total	% alive mice
4/10	40
5/5	100
4/5	80
4/5	80
4/5	80
3/5	60
2/5	40

Example 41

IL-1 is one of the main mediators of septic shock *in vivo*. In order to determine the inhibitive activity of AG1714 on production of IL-1 from cells incubated with LPS, human peripheral blood monocytes (PBM) at a concentration of 2×10^6 cells/ml were divided into the following groups:

- i. Cells grown in growth medium alone;
- ii. Cells grown in growth medium to which AG1714 was added ($20 \mu\text{M}$);
- iii. Cells grown in growth medium to which LPS was added (10 mg/ml); and
- iv. Cells grown in growth medium with the addition of LPS (10 mg/ml) and AG1714 ($20 \mu\text{M}$). The cells were incubated for 24 hours and the amount of IL-1 β was determined using the Genzyme ELISA kit.

As seen in Table 11, which shows two experiments carried out as described above, addition of AG1714 to cells incubated with LPS significantly reduced the amount of IL-1 β produced by the cells.

- 51 -

Table 11

**Inhibition by AG1714 of LPS-induced IL-1 β production
in human peripheral mononuclear cells**

		IL-1 β pg/ml AG1714 (20 μ M)	
Exp. 1		-	+
	None	2522	1174
	LPS (10 μ g/ml)	10187	1230
Exp. 2		-	-
	None	583	648
	LPS (10 μ g/ml)	9309	970

The above results indicate that tyrphostins may be useful in reducing the non desired IL-1 mediated effect involved in septic shock.

The results of the above three examples indicate that tyrphostins 5 may be useful in reducing or preventing the development of septic shock during an inflammatory response. The tyrphostins may also be useful as anti-inflammatory agents and in counteracting pathogenetic effects mediated by various cytokines (e.g. TNF and IL-1) which occur for example in autoimmunity.

- 52 -

CLAIMS:

1. Pharmaceutical compositions for countering damage to cells or tissue comprising an effective amount of a compound of the general formula

5




10

wherein:

- Ar is a group of the formulae


15



20

- n is 0 or, when Ar has the formula (i) above, then n may also be 1,
- R is CN, -C(S)NH₂, -C(O)NHR₃ or, when R₁ is 4-NO₂ and R₂ is H or 3-OH, then R may also be a group of the formula

25




30

- where R₃ is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
- R₁ and R₂ are each independently H, OH, NO₂ or, when R is CN, also CH₃, F, or CF₃, provided that both R₁ and R₂ are not simultaneously H, together with a pharmaceutically acceptable carrier.

- 53 -

2. Pharmaceutical compositions according to Claim 1, comprising a compound of formula I wherein R is CN, -C(S)NH₂, -C(O)NHCH₂C₆H₅ or a group of the formula

5



and n is 0, R₁ is 4-NO₂ and R₂ is H.

- 10 3. Pharmaceutical compositions according to Claim 1 or 2, for countering damage caused by a cytotoxic drug.

4. Pharmaceutical compositions according to Claim 3, for countering damage caused by an anti-neoplastic drug.

- 15 5. Pharmaceutical compositions according to Claim 3 or 4, comprising an effective amount of a compounds of formula I in Claim 1, in combination with a cytotoxic drug.

6. Pharmaceutical compositions according to any one of Claims 3-5, wherein the drug is selected from the group consisting of cisplatin, doxorubicin, cyclophosphamide, mitomycin-C and 5-fluorouracil.

- 20 7. A pharmaceutical composition according to any one of Claims 1-6, for countering myelotoxicity and lymphotoxicity.

8. Pharmaceutical compositions according to any of the preceding claims in a form suitable for intravenous administration.

9. Pharmaceutical compositions according to any of the preceding claims in a form suitable for oral administration.

- 25 10. Pharmaceutical compositions according to Claim 1 or 2, for use in *ex vivo* preservation of cells, tissue or organ.

11. Pharmaceutical compositions according to Claim 1 or 2, for countering damage caused by an immune mediated or inflammatory response.

- 30 12. A pharmaceutical composition according to any one of Claims 1-10, for countering undesired apoptosis.

- 54 -

13. A method of treatment of an individual, for countering damage to cells, tissue or organ, said method comprising administering to the individual an effective amount of a compound of the general formula

5




10)

wherein:

- Ar is a group of the formulae

15




(i)

(ii)

20

- n is 0 or, when Ar has the formula (i) above, then n may also be 1, R is CN, $-\text{C}(\text{S})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}_3$ or, when R_1 is 4- NO_2 and R_2 is H or 3-OH, then R may also be a group of the formula

25




30

where R_3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
 - R_1 and R_2 are each independently H, OH, NO_2 or, when R is CN, also CH_3 , F, or CF_3 , provided that both R_1 and R_2 are not simultaneously H, together with a pharmaceutically acceptable carrier.

14. A method according to Claim 13, wherein in the compound of formula I, R is CN, -C(S)NH₂, -C(O)NHCH₂C₆H₅ or a group of the formula

5



and n is 0, R₁ is 4-NO₂ and R₂ is H.

15. A method according to Claim 13 or 14, wherein the harmful agent is a cytotoxic drug.

16. A method according to Claim 15, wherein the anti-cytotoxic drug is an anti-neoplastic drug.

17. A method according to Claim 16, wherein the cytotoxic drug is selected from the group consisting of cisplatin, doxorubicin, cyclophosphamide, mitomycin-C and 5-fluorouracil.

18. A method according to any one of Claims 13-17, for countering myelotoxicity and lymphotoxicity.

19. A method according to Claim 12, for countering undesired harmful effects of irradiation treatment.

20. A method according to any one of Claims 13 to 19, wherein the compound of formula I is administered in combination with the cytotoxic drug or irradiation treatment.

21. A method according to any one of Claims 1 to 20, wherein the compound of formula I is administered prior to the administration of the cytotoxic drug or the irradiation treatment.

22. A method according to any one of Claims 13 to 21, wherein the compound of formula I is administered intravenously.

23. A method according to any one of Claims 13 to 21, wherein the compounds of formula I is administered orally.

30. 24. A method according to Claim 13 or 14, for countering damage caused by an immune mediated or inflammatory response.

- 56 -

25. A method for *ex vivo* preservation of organ, tissue or cells comprising contacting the organ, tissue or cells *ex vivo* with a compound of the general formula

5




10

wherein:

- Ar is a group of the formulae


15



20

- n is 0 or, when Ar has the formula (i) above, then n may also be 1,
- R is CN, -C(S)NH₂, -C(O)NHR₃ or, when R₁ is 4-NO₂ and R₂ is H or 3-OH, then R may also be a group of the formula

25




30

- where R₃ is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
- R₁ and R₂ are each independently H, OH, NO₂ or, when R is CN, also CH₃, F, or CF₃, provided that both R₁ and R₂ are not simultaneously H, together with a pharmaceutically acceptable carrier.

- 57 -



26. Compound of the general formula



5 wherein


- Ar is a group of the formula

10



- n is 0, or, when Ar has the formula (i) above, then n may also be 1,
- R is -CN, -C(S)NH₂, -C(O)NHR₃ or, where R₁ is 4-NO₂ and R₂ is H, then R may also be a group of the formulae

20



25

R₁ and R₂ are each independently H, OH, NO₂ or, when R is CN, also CH₃, F or CF₃; and

R₃ is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;

with the provisos that:


30

- a) when R is CN and n is 0, then
 - (aa) if one of R₁ and R₂ is H or OH, then the other cannot represent NO₂;
 - (ab) if one of R₁ and R₂ is H or F, then the other cannot represent H or F; and
- b) when R₁ is 4-NO₂, R₂ is H and n is 0, then R cannot represent -C(O)NH₂ or -C(S)NH₂.

- 58 -

27. Compound according to Claim 26, wherein R is CN, -C(S)NH₂, -C(O)NHCH₂C₆H₅ or a group of the formula

5



and n is 0, R₁ is 4-NO₂, R₂ is H and n is 0.

1/25




FIG. 1B




FIG. 1A

2/25




FIG. 2




FIG.3




FIG.4

4/25




FIG. 5

5/25




FIG. 6B




FIG. 6A

6/25




FIG.7A




FIG.7B

7/25



FIG.7C




FIG.7D

8/25




FIG.7E



FIG.7F

9/25




FIG.8




FIG.9

10/25




FIG. 10




FIG. 11

11/25




FIG. 12B




FIG. 12A

12/25




FIG. 13B




FIG. 13A

13/25




FIG. 14B




FIG. 14A

14/25




FIG. 16




FIG. 15

15/25




FIG. 17

16/25




FIG.18

17/25




FIG.19

18/25




FIG.20

19/25




FIG.21A




FIG.21B




FIG.21C




FIG.22




FIG.23

21/25




FIG.24

22/25




FIG.25A




FIG.25B

23/25




FIG.26






FIG.27



25/25




FIG.30

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 97/00276

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/275 A61K31/415 A61K31/425 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 24190 A (SUGEN) 14 September 1995 see page 12, line 6 - line 30 see page 18 - page 23 see page 35 - page 42 see page 45, line 5 - line 8 see page 49 see page 50, line 1 - line 12 see page 73 - page 83 see claims	1,5,6,9, 11,13, 20-24,26
A	---	15-17
X	WO 95 14464 A (YISSUM RES. DEV. CO. HEBREW UNIV. JERUSALEM) 1 June 1995 see the whole document ---	1,8,9, 11,13, 22-24,26
		-/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search

27 November 1997

Date of mailing of the international search report

09.01.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 97/00276

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEVITSKI: "Tyrosine kinase inhibition: an approach to drug development" SCIENCE, vol. 267, 24 March 1995, pages 1782-1788, XP002048355 cited in the application see the whole document ---	1,5,11, 13,20, 24,26
X	VANICHKIN: "Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity" J. INFECT. DIS., vol. 173, no. 4, April 1996, pages 927-933, XP002048356 see the whole document ---	1,3,5, 11,15,24
X	EP 0 322 738 A (YISSUM RES. DEV. CO. HEBREW UNIV. JERUSALEM) 5 July 1989 see the whole document ---	1,13,26
X	SZENDE: "Tyrphostin induces non-apoptotic programmed cell death in colon tumor cells" CELL. BIOL. INT., vol. 19, no. 11, 1995, pages 903-911, XP002048357 see the whole document ---	1,5,13
A	---	3,4,6,12
X	ANDERSON: "Changes in the survival curve shape of E. coli cells following irradiation in the presence of uncouplers of oxidative phosphorylation" INT. J. RADIAT. BIOL. RELAT. STUD. PHYS., vol. 48, no. 4, 1985, pages 495-504, XP002048358 see the whole document ---	13,19
X	WO 95 02420 A (SPRINGER) 26 January 1995 see the whole document ---	1,2,8,9, 13,22, 23,26
X	GATELY: "Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153" BR. J. CANCER, vol. 73, no. 1, January 1996, pages 18-23, XP002048359 see the whole document ---	1,5,6,26
-/-		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 97/00276

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NOVOGROSKY: "Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors" SCIENCE, vol. 264, no. 5163, 27 May 1994, pages 1319-1322, XP002048360 see the whole document ---	1,11,13, 24
X	AKARASEREEMONT: "The induction of cyclo-oxygenase-2 in human pulmonary epithelial cell culture (A549) activated by IL-1beta is inhibited by tyrosine kinase inhibitors" BIOCHEM. BIOPHYS. RES. COMMUN., vol. 220, no. 1, 7 May 1996, pages 181-185, XP002048361 see the whole document ---	1,11,13, 24
X	US 3 726 662 A (R. K. HOWE) 10 April 1973 see the whole document ---	26
X	DE 28 00 740 A (CIBA-GEIGY AG) 13 July 1978 see the whole document	26
A	---	27
X	GAZIT: "Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors" J. MED. CHEM., vol. 32, no. 19, 1989, pages 2344-2352, XP002048362 see page 2346, table I compounds 13,19,22,23 see page 2347, table III compounds 46-50 ---	26
X	EP 0 537 949 A (LILLY IND. LTD) 21 April 1993 see page 7, line 35 ---	26,27
P,X	WO 96 25949 A (BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS) 29 August 1996 see the whole document, especially page 16, page 34 lines 13-25, page 36 and claims ---	1-6, 13-17
P,X	WO 97 11692 A (OSTEOARTHRITIS SCIENCES INC.) 3 April 1997 see the whole document, especially claims 1,5, page 27 lines 21-22, pages 29-32 ---	1,8,9, 13, 22-24,26
1		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 97/00276

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 19169 A (SUGEN) 20 July 1995 see page 17 see page 26 - page 32 see page 76 - page 81 see page 97 claims -----	1,2,5,6, 11,13, 14,24, 26,27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IL 97/00276

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9524190 A	14-09-95	AU 2096895 A		25-09-95

WO 9514464 A	01-06-95	AU 1293595 A CA 2177289 A EP 0731697 A		13-06-95 01-06-95 18-09-96

EP 322738 A	05-07-89	AT 120955 T AU 632992 B AU 2736088 A CA 1334826 A DE 3853577 D DE 3853577 T EP 0614661 A ES 2073398 T JP 2138238 A US 5217999 A		15-04-95 21-01-93 29-06-89 21-03-95 18-05-95 31-08-95 14-09-94 16-08-95 28-05-90 08-06-93

WO 9502420 A	26-01-95	AU 7190794 A EP 0708660 A HU 74451 A JP 9500125 T		13-02-95 01-05-96 30-12-96 07-01-97

US 3726662 A	10-04-73	NONE		

DE 2800740 A	13-07-78	AU 3228078 A BE 862750 A DK 9078 A FR 2376661 A NL 7800191 A SE 7800189 A US 4151298 A ZA 7800114 A		19-07-79 10-07-78 11-07-78 04-08-78 12-07-78 11-07-78 24-04-79 25-10-78

EP 537949 A	21-04-93	AU 658003 B AU 2621692 A CA 2079428 A CN 1073437 A CZ 281688 B JP 5194477 A MX 9205714 A		30-03-95 22-04-93 10-04-93 23-06-93 11-12-96 03-08-93 01-04-93

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL 97/00276

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 13-24 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IL 97/00276

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 537949 A		NO 301587 B NZ 244627 A RU 2071472 C US 5284868 A ZA 9207717 A	17-11-97 22-12-94 10-01-97 08-02-94 07-04-94
WO 9625949 A	29-08-96	EP 0804240 A	05-11-97
WO 9711692 A	03-04-97	AU 7107496 A	17-04-97
WO 9519169 A	20-07-95	AU 1563395 A CA 2180658 A CN 1128496 A EP 0804191 A US 5610173 A	01-08-95 20-07-95 07-08-96 05-11-97 11-03-97